Share this
Cooley Named Licensing & Collaboration Firm of the Year by LMG Life Sciences
Two Cooley partners also named winners in their practice areas • September 9, 2022
Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche
Poseida to receive $110 million upfront, with overall potential deal value of up to $6 billion • August 5, 2022
Turning Point Therapeutics to Sell to Bristol Myers Squibb for $4.1 Billion
June 3, 2022
Poseida Therapeutics Enters Research Collaboration With Takeda to Develop Novel Gene Therapies
November 17, 2021
Shoreline Biosciences Enters Collaboration With BeiGene to Develop Genetically Modified Cell Therapies
June 24, 2021